Clinical Trial Update: Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of atezolizumab plus bevacizumab in chemotherapy-resistant, MSI-like colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: MSI, ColoRectal Cancer | Phase 2 | Status: TERMINATED